VistaGen Therapeutics VTGN reported its Q3 earnings results on Thursday, February 10, 2022 at 05:00 PM.
Here's what investors need to know about the announcement.
Earnings
VistaGen Therapeutics beat estimated earnings by 28.57%, reporting an EPS of $-0.05 versus an estimate of $-0.07.
Revenue was up $44.30 thousand from the same period last year.
Past Earnings Performance
Last quarter the company missed on EPS by $0.01, which was followed by a 4.0% increase in the share price the next day.
Here's a look at VistaGen Therapeutics's past performance:
| Quarter | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 |
|---|---|---|---|---|
| EPS Estimate | -0.06 | -0.05 | -0.05 | -0.05 |
| EPS Actual | -0.07 | -0.04 | -0.30 | -0.07 |
| Revenue Estimate | 260.00K | 380.00K | 230.00K | 210.00K |
| Revenue Actual | 358.00K | 354.10K | 441.90K | 313.60K |
To track all upcoming earnings announcements, click to use Benzinga Earnings Calendar.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
